Plain-English translation of NCT01581294 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a long-term study that follows people with inflammatory arthritis (like rheumatoid arthritis or psoriatic arthritis) who are starting a new biological disease-modifying medication or kinase inhibitor. Researchers will track how safe and effective the medication is by collecting information from regular clinic visits and blood tests over many years.
Biological arthritis medications help many patients, but doctors need real-world information about how these treatments work over the long term, what side effects people experience, and which patients benefit most. This study builds that knowledge by carefully monitoring patients in regular clinical care rather than in a controlled research setting.
You likely qualify if…
You likely don't qualify if…
You would attend clinic visits at the start of your new medication, then again at 3 months, 6 months, 12 months, and once yearly after that for as long as you continue the study. At each visit, your doctor will assess how you're doing, ask about your symptoms and side effects, measure inflammation in your blood, and may collect blood samples for research. The study uses information already gathered in routine care, so it fits into your normal appointments.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Norway